Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’
"Very small investment” in gene editing/sequencing on cards
Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.
